KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Income from Non-Controlling Interests (2017 - 2026)

Amneal Pharmaceuticals has reported Income from Non-Controlling Interests over the past 9 years, most recently at $14.5 million for Q4 2025.

  • For Q4 2025, Income from Non-Controlling Interests rose 40.22% year-over-year to $14.5 million; the TTM value through Dec 2025 reached $55.9 million, up 29.91%, while the annual FY2025 figure was $55.9 million, 29.91% up from the prior year.
  • Income from Non-Controlling Interests for Q4 2025 was $14.5 million at Amneal Pharmaceuticals, down from $15.8 million in the prior quarter.
  • Over five years, Income from Non-Controlling Interests peaked at $17.8 million in Q2 2023 and troughed at -$119.3 million in Q2 2022.
  • A 5-year average of $923100.0 and a median of $10.2 million in 2024 define the central range for Income from Non-Controlling Interests.
  • Biggest five-year swings in Income from Non-Controlling Interests: plummeted 776.0% in 2022 and later surged 5034.11% in 2023.
  • Year by year, Income from Non-Controlling Interests stood at -$14.1 million in 2021, then skyrocketed by 89.17% to -$1.5 million in 2022, then surged by 447.87% to $5.3 million in 2023, then soared by 94.89% to $10.3 million in 2024, then surged by 40.22% to $14.5 million in 2025.
  • Business Quant data shows Income from Non-Controlling Interests for AMRX at $14.5 million in Q4 2025, $15.8 million in Q3 2025, and $13.2 million in Q2 2025.